Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention
Conditions
Interventions
Erenumab
Placebo
Locations
129
United States
Research Site
Phoenix, Arizona, United States
Research Site
Anaheim, California, United States
Research Site
Encino, California, United States
Research Site
Irvine, California, United States
Research Site
Los Alamitos, California, United States
Research Site
Newport Beach, California, United States
Start Date
July 17, 2015
Primary Completion Date
September 5, 2016
Completion Date
June 19, 2017
Last Updated
October 12, 2022
NCT06735833
NCT06241313
NCT06641466
NCT07018713
NCT04715685
NCT07476053
Lead Sponsor
Amgen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions